Henan Cancer Hospital

This study is testing two different dosing schedules of a three-drug combination (chemotherapy plus an immunotherapy drug) given before surgery for early triple-negative breast cancer. The goal is to see which schedule is more effective at completely eliminating cancer from the b…

This study is testing a new three-drug combination for people with advanced stomach or gastroesophageal cancer that has a specific marker called HER2-positive. The main goals are to find the safest and most effective dose of the new drug fruquintinib when added to two standard ca…

This early-stage trial is testing a new T cell therapy called RE002 for people with advanced solid tumors that have a specific KRAS G12D mutation. Researchers will enroll 30 patients to evaluate the safety of three different dose levels and see if the treatment shows any anti-tum…

This early-stage study is testing a new treatment called BioTTT001 for people with advanced non-small cell lung cancer that has spread to the lining of the brain (meningeal metastasis). BioTTT001 is a modified virus designed to infect and kill cancer cells. The main goals are to …

This study is observing how well and how safely a combination of two drugs, zanubrutinib and rituximab, works as the first treatment for people with marginal zone lymphoma. It will follow 30 patients who have not had prior systematic treatment for their cancer. The main goal is t…

This study is testing whether adding an experimental drug called QL1706 to standard chemotherapy works better than chemotherapy alone when given before surgery for a common type of breast cancer (HR+/HER2-). It will involve 238 women to see if the combination helps eliminate all …

This study is testing a new injection called efbemalenograstim alfa-vuxw to see if it can prevent a dangerous side effect of chemotherapy called febrile neutropenia. Febrile neutropenia is a severe drop in infection-fighting white blood cells, which can lead to life-threatening i…

This study aims to see if a new blood analysis technology can predict how well patients with advanced small cell lung cancer will respond to a standard first-line treatment. The treatment combines an immunotherapy drug (tislelizumab) with chemotherapy. Researchers will analyze bl…